Drug intelligence / Profile preview

MAX-9

Development stage: Preclinical
Lead developer: Guangzhou Zaiji Medical Technology
Modality: Small Molecules
Administration: Transdermal

Overview

MAX-9 is a preclinical-stage small molecule drug candidate being developed by Maxinovel for the treatment of hair loss. It is designed for transdermal administration, which may offer localized delivery and potentially reduce systemic side effects. As of current pipeline information, the specific biological target and molecular mechanism of action for MAX-9 have not been publicly disclosed by the developer.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on MAX-9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAX-9.

Explore the full profile